AR112101A1 - Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll). - Google Patents

Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).

Info

Publication number
AR112101A1
AR112101A1 ARP180101622A ARP180101622A AR112101A1 AR 112101 A1 AR112101 A1 AR 112101A1 AR P180101622 A ARP180101622 A AR P180101622A AR P180101622 A ARP180101622 A AR P180101622A AR 112101 A1 AR112101 A1 AR 112101A1
Authority
AR
Argentina
Prior art keywords
tinostamustine
pll
leukemia
cell
prolinphocytic
Prior art date
Application number
ARP180101622A
Other languages
English (en)
Inventor
Marco Herling
Thomas Jorg Mehrling
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of AR112101A1 publication Critical patent/AR112101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se provee tinostamustina de fórmula (1), o una sal farmacéuticamente aceptable para su uso en el tratamiento de-leucemia prolinfocítica de célula T (T-PLL) en un paciente que la necesita.
ARP180101622A 2017-06-13 2018-06-13 Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll). AR112101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709402.0A GB201709402D0 (en) 2017-06-13 2017-06-13 Compounds for treating t-pll

Publications (1)

Publication Number Publication Date
AR112101A1 true AR112101A1 (es) 2019-09-18

Family

ID=59358363

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101622A AR112101A1 (es) 2017-06-13 2018-06-13 Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).

Country Status (14)

Country Link
US (2) US11318117B2 (es)
EP (1) EP3638231B1 (es)
JP (1) JP7195283B2 (es)
KR (1) KR102655833B1 (es)
AR (1) AR112101A1 (es)
AU (1) AU2018285821A1 (es)
BR (1) BR112019026484A2 (es)
CA (1) CA3067276A1 (es)
ES (1) ES2966954T3 (es)
GB (1) GB201709402D0 (es)
IL (1) IL271017A (es)
MX (1) MX2019015208A (es)
TW (1) TW201919616A (es)
WO (1) WO2018229132A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
WO2020128913A1 (en) * 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating multiple myeloma
US20220354951A1 (en) * 2019-08-02 2022-11-10 Onehealthcompany, Inc. Treatment of Canine Cancers

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
GB9126209D0 (en) 1991-12-10 1992-02-12 Orion Yhtymae Oy Drug formulations for parenteral use
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5882941A (en) 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6133248A (en) 1997-06-13 2000-10-17 Cydex, Inc. Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
AU2001273413A1 (en) 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1335898B1 (en) 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AU2002243231A1 (en) 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
CN1764648A (zh) 2003-01-13 2006-04-26 安斯泰来制药有限公司 作为组蛋白脱乙酰酶(hdac)抑制剂的异羟肟酸衍生物
US7652036B2 (en) 2003-02-25 2010-01-26 Topotarget Uk Limited Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
JP2007501775A (ja) 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
EP1745022B1 (en) 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
DK1901729T3 (da) 2005-05-13 2012-05-14 Topotarget Uk Ltd Farmaceutiske formuleringer af HDAC-inhibitorer
CN101528215B (zh) 2006-10-20 2011-10-19 艾科斯有限公司 Chk1抑制剂和环糊精的组合物
GB0621160D0 (en) 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101084876A (zh) 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
US20090131367A1 (en) 2007-11-19 2009-05-21 The Regents Of The University Of Colorado Combinations of HDAC Inhibitors and Proteasome Inhibitors
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CN102164579B (zh) 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
CN102177140B (zh) 2008-10-08 2016-01-27 赛福伦公司 用于制备苯达莫司汀的方法
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
PL2389375T3 (pl) 2009-01-23 2015-11-30 Euro Celtique Sa Pochodne kwasu hydroksamowego
RU2734236C2 (ru) 2009-02-25 2020-10-13 Софткемо Фарма Корп. Композиции бендамустина и циклополисахарида
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011017448A1 (en) 2009-08-05 2011-02-10 The Trustees Of The University Of Pennsylvania Use of histone deacetylase inhibitors for treatment of autoimmune diseases
CN101928234B (zh) 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP5727000B2 (ja) 2010-04-16 2015-06-03 ツェルアクト ファーマ ゲーエムベーハー 腫瘍の処置のためのエポトシドのアナログ
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
US8748470B2 (en) 2011-03-17 2014-06-10 The University Of Chicago Methods for treating ovarian cancer by inhibiting fatty acid binding proteins
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
CN102993102B (zh) 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
KR20140078619A (ko) 2011-09-18 2014-06-25 유로-셀띠끄 소시에떼 아노님 약학적 조성물
ES2616242T3 (es) 2011-09-28 2017-06-12 Euro-Celtique S.A. Derivados de mostaza de nitrógeno
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
NZ630314A (en) 2014-02-18 2016-03-31 Celgene Corp Combination therapy for hematological malignancies
GB201409485D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP2017537164A (ja) 2014-12-05 2017-12-14 ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ
CN106580971B (zh) 2015-10-20 2019-11-12 杭州梯诺医药科技有限公司 一种药物组合物及其制备方法
AU2016426574B2 (en) 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
US20180098969A1 (en) 2016-10-11 2018-04-12 Purdue Pharmaceutical Products L.P. Hodgkin lymphoma therapy
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
WO2020128913A1 (en) 2018-12-18 2020-06-25 Mundipharma International Corporation Limited Compounds for treating multiple myeloma

Also Published As

Publication number Publication date
US20220401417A1 (en) 2022-12-22
AU2018285821A1 (en) 2019-12-19
JP7195283B2 (ja) 2022-12-23
WO2018229132A1 (en) 2018-12-20
EP3638231C0 (en) 2023-12-20
IL271017A (en) 2020-01-30
EP3638231A1 (en) 2020-04-22
CA3067276A1 (en) 2018-12-20
TW201919616A (zh) 2019-06-01
ES2966954T3 (es) 2024-04-25
US11318117B2 (en) 2022-05-03
KR102655833B1 (ko) 2024-04-08
MX2019015208A (es) 2022-05-03
KR20200015563A (ko) 2020-02-12
BR112019026484A2 (pt) 2020-07-14
JP2020523359A (ja) 2020-08-06
EP3638231B1 (en) 2023-12-20
GB201709402D0 (en) 2017-07-26
US11918558B2 (en) 2024-03-05
US20200113871A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
CL2019003126A1 (es) Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak.
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CR20190124A (es) Inhibidores de ssao de aminopirimidina
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
CL2016001756A1 (es) Preparación farmacéutica que comprende 0,001-0,003 pv de 6-4-pirazol-1-ilbencilpiridin-3-ilsulfonilaminometilpiridin-2-ilaminoacetato de isopropilo o una sal del mismo uso para el tratamiento o prevención de glaucoma o hipertensión ocular.
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
UY38096A (es) Inhibidores de arginasa y sus métodos de uso
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MD3395820T2 (ro) Compuși antitumorali
CL2019000377A1 (es) Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
UY26920A1 (es) 7 - oxo piridopirimidinas
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.

Legal Events

Date Code Title Description
FB Suspension of granting procedure